Moonlake Immunotherapeutics · NASDAQ:MLTX

Bodenstedt Matthias sold 17,876 Moonlake Immunotherapeutics shares (Form 4)

Traded Jun 17 to Jun 18, 2026 · Filed Jun 18, 2026

From Jun 17 to Jun 18, 2026, Bodenstedt Matthias (Chief Financial Officer) sold 17,876 Moonlake Immunotherapeutics shares at an average US$19.67 for US$352K under a trading plan, leaving 1,154,555 shares. Filed Jun 18, 2026 (Form 4).

Sold
17,876 shares
Price
US$19.67 average (US$19.60 to US$19.68)
Value
US$352K
Holding after
1,154,555 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Financial Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jun 17, 2026Class A ordinary shares, par value $0.0001 per shareSale15,082US$19.681,157,349Direct
Jun 18, 2026Class A ordinary shares, par value $0.0001 per shareSale2,794US$19.601,154,555Direct

Source

View original at SEC

Related